Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Hydroxyurea
Drug ID BADD_D01110
Description An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
Indications and Usage For management of melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary and Sickle-cell anemia.
Marketing Status Prescription; Discontinued
ATC Code L01XX05
DrugBank ID DB01005
KEGG ID D00341
MeSH ID D006918
PubChem ID 3657
TTD Drug ID D07CWD
NDC Product Code 70518-0916; 0904-6939; 51927-0072; 49452-3650; 0003-6337; 60429-265; 55154-7143; 0003-0830; 10135-702; 71770-120; 49884-724; 55512-0003; 68084-284; 51552-0851; 17337-0022; 0003-6336; 35369-0006; 0555-0882; 0003-6335; 42291-321; 51927-2655; 71052-323; 69315-164; 17337-0023; 71770-105
Synonyms Hydroxyurea | Hydroxycarbamid | Oncocarbide | Hydrea
Chemical Information
Molecular Formula CH4N2O2
CAS Registry Number 127-07-1
SMILES C(=O)(N)NO
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Chronic myeloid leukaemiaTyrosine-protein kinase ABL1P00519T6350511841409; 11273186; 9516377; 15510207
HepatomegalyTyrosine-protein kinase ABL1P00519T6350511841409; 11273186; 9516377; 15510207
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Lymphadenopathy01.09.01.0020.000533%Not Available
Lymphocytosis01.02.01.0030.000533%Not Available
Lymphoma16.20.01.001; 01.12.01.0010.000417%Not Available
Lymphopenia01.02.02.0020.000533%Not Available
Malaise08.01.01.003--
Malaria11.06.04.001; 01.03.02.0070.000799%Not Available
Melaena24.07.02.013; 07.12.02.0040.000533%Not Available
Memory impairment17.03.02.003; 19.20.01.003--
Metabolic acidosis14.01.01.0030.000533%Not Available
Methaemoglobinaemia01.05.01.0020.000533%
Mouth ulceration07.05.06.0040.000533%Not Available
Movement disorder17.01.02.0100.000533%Not Available
Mucosal inflammation08.01.06.0020.000533%Not Available
Muscle haemorrhage24.07.01.037; 15.05.03.0170.000799%Not Available
Muscle spasms15.05.03.004--
Muscular weakness17.05.03.005; 15.05.06.0010.001066%
Myalgia15.05.02.001--
Myelodysplastic syndrome01.10.04.001; 16.01.04.0010.000764%
Myelofibrosis16.21.03.001; 01.13.03.0050.002363%Not Available
Myocardial infarction24.04.04.009; 02.02.02.007--
Nail dystrophy23.02.05.0030.000533%Not Available
Nausea07.01.07.001--
Neoplasm16.16.02.001--Not Available
Nervous system disorder17.02.10.0010.000533%Not Available
Neuroendocrine carcinoma of the skin16.03.02.008; 05.08.01.009; 23.08.02.0080.000139%Not Available
Neuropathy peripheral17.09.03.003--Not Available
Neutropenia01.02.03.0040.002131%Not Available
Neutrophil count decreased13.01.06.0100.001066%
Neutrophil count increased13.01.06.0110.000799%Not Available
Night sweats23.02.03.006; 08.01.03.0310.000533%Not Available
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 14 Pages